Skip to main content

The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis

Biological Trace Element Research volume 199, pages 4516–4524 (2021)Cite this article

Abstract

Fibroblast growth factor 23 (FGF23) gene is found to be responsible for autosomal dominant hypophosphatemic rickets, and is highly expressed in chronic kidney disease (CKD) and end-stage renal disease patients with iron deficiency anemia (IDA). We evaluated the efficacy of different iron treatments on FGF23 levels in dialysis-dependent and non-dialysis-dependent CKD patients with IDA. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing different types of iron treatment versus placebo in CKD patients up to May 2020. We investigated the efficacy of iron treatment on the levels of FGF23 and C-terminal FGF23 (cFGF23) in CKD patients. We estimated weighted mean differences (WMDs) and 95% confidence intervals (CIs) using the random-effects model. Nine studies with 11 arms were included in the meta-analysis. Overall, iron treatment showed a significant reduction in FGF23 levels compared to control group (WMD: − 60.56 pg/ml, 95% CI: − 92.17, − 28.95). Compared to placebo, subgroup analysis showed that oral iron therapy (WMD: − 6.98 pg/ml, 95% CI: − 10.66, − 3.31) was more effective than intravenous (IV) iron therapy (WMD: 4.90 pg/ml, 95% CI: − 12.03, 21.83) on FGF23 levels. There was no significant change in cFGF23 levels between iron treatment and control group (WMD: − 64.72 Ru/ml, 95% CI: − 147.69, 18.25). Subgroup analysis showed that oral iron therapy resulted in a significant reduction in cFGF23 levels compared to control group (WMD: − 150.48 RU/ml, 95% CI: − 151.31, − 149.65). In conclusion, iron treatment was associated with a significant decrease in FGF23 levels in CKD patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB et al (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 39010105:1888–1917

    Article  Google Scholar 

  2. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M et al (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 39510225:709–733

    Article  Google Scholar 

  3. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR (2020) Targeting the progression of chronic kidney disease. Nat Rev Nephrol 165:269–288

    Article  Google Scholar 

  4. Fukumoto S. Chapter 63 - fibroblast growth factor 23. In: Bilezikian JP, Martin TJ, Clemens TL, Rosen CJ, editors. Principles of bone biology (fourth edition): Academic Press; 2020. p. 1529–38

  5. Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV (2020) Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag 16:245–259

    CAS  Article  Google Scholar 

  6. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V et al (2016) Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 891:135–146

    Article  Google Scholar 

  7. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE et al (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 655:728–736

    Article  Google Scholar 

  8. Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 288:1793–1803

    Article  Google Scholar 

  9. Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M et al (2019) A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 308:1495–1504

    Article  Google Scholar 

  10. Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K et al (2019) Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrology Dialysis Transplantation. 347:1115–1124

    Article  Google Scholar 

  11. Honda H, Tanaka K, Michihata T, Shibagaki K, Yuza T, Hirao K et al (2019) Differential impacts of intravenous iron administration and iron-containing phosphate binders on serum intact fibroblast growth factor 23 levels. Blood Purif 472:63–69

    Article  Google Scholar 

  12. Huang LL, Lee D, Troster SM, Kent AB, Roberts MA, Macdougall IC et al (2018) A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrology Dialysis Transplantation 339:1628–1635

    Google Scholar 

  13. Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ et al (2018) Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. Clin Exp Nephrol 224:789–796

    Article  Google Scholar 

  14. Maruyama N, Otsuki T, Yoshida Y, Nagura C, Kitai M, Shibahara N et al (2018) Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients. Am J Nephrol 476:406–414

    Article  Google Scholar 

  15. Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K et al (2019) Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 91:1–9

    Google Scholar 

  16. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K et al (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 93:543–552

    Article  Google Scholar 

  17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 67:e1000097

    Article  Google Scholar 

  18. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials 2020 [updated 2020/12/29/. Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials

  19. Jackson D, White IR, Thompson SG (2010) Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 2912:1282–1297

    Article  Google Scholar 

  20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj. 3277414:557–560

    Article  Google Scholar 

  21. Harre FE Jr, Lee KL, Pollock BG (1988) Regression models in clinical studies: determining relationships between predictors and response. JNCI: Journal of the National Cancer Institute 8015:1198–1202

    Article  Google Scholar 

  22. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj. 3157109:629–634

    Article  Google Scholar 

  23. Begg CB (1994) Publication bias. The handbook of research synthesis 25:299–409

    Google Scholar 

  24. Tan S, Satake S, Smith E, Toussaint N, Hewitson T, Holt S (2017) Parenteral iron polymaltose changes i: c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. Eur J Clin Nutr 712:180–184

    Article  Google Scholar 

  25. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG (2009) FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. The Journal of Clinical Endocrinology & Metabolism 947:2332–2337

    Article  Google Scholar 

  26. White KE, Hum JM, Econs MJ (2014) Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis. Current osteoporosis reports 123:252–262

    Article  Google Scholar 

  27. Suresh K, Chandrashekara S (2012) Sample size estimation and power analysis for clinical research studies. Journal of Human Reproductive Sciences 51:7

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA

    Ahmed Abu-Zaid

  2. College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

    Ahmed Abu-Zaid

  3. School of Public Health, The University of Memphis, Memphis, TN, USA

    Duha Magzoub

  4. Unaizah College of Medicine and Medical Sciences, Qassim University, Buraydah, Al-Qassim, Saudi Arabia

    Mohammad Abdulrahman Aldehami

  5. Faculty of Medicine, King Abdulaziz University Rabigh Branch, Rabigh, Saudi Arabia

    Abdulrahman Adel Behiry

  6. Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates

    Akshaya Srikanth Bhagavathula

  7. Medicine Faculty of Sousse, University of Sousse, 4000, Sousse, Tunisia

    Raouf Hajji

  8. Internal Medicine Department, Sidi Bouzid Hospital, 9100, Sidi Bouzid, Tunisia

    Raouf Hajji

Authors
  1. Ahmed Abu-Zaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Duha Magzoub
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Abdulrahman Aldehami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdulrahman Adel Behiry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akshaya Srikanth Bhagavathula
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raouf Hajji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Abu-Zaid.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 26 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abu-Zaid, A., Magzoub, D., Aldehami, M.A. et al. The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis. Biol Trace Elem Res 199, 4516–4524 (2021). https://doi.org/10.1007/s12011-021-02598-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12011-021-02598-1

Keywords

  • Ferric citrate
  • Anemia
  • Iron
  • Renal dialysis
  • Chronic kidney disease